Motivation: It is hoped that advances in our knowledge in disease genomics will contribute to personalized medicine such as individualized preventive strategies or early diagnoses of diseases. With the growth of genome-wide association studies (GWAS) in the past decade, how far have we reached this goal? In this study we explored the predictive ability of polygenic risk scores (PRSs) derived from GWAS for a range of complex disease and traits. Results: We first proposed a new approach to evaluate predictive performances of PRS at arbitrary P-value thresholds. The method was based on corrected estimates of effect sizes, accounting for possible false positives and selection bias. This approach requires no distributional assumptions and only requires summary statistics as input. The validity of the approach was verified in simulations. We explored the predictive power of PRS for ten complex traits, including type 2 diabetes (DM), coronary artery disease (CAD), triglycerides, high-and low-density lipoprotein, total cholesterol, schizophrenia (SCZ), bipolar disorder (BD), major depressive disorder and anxiety disorders. We found that the predictive ability of PRS for CAD and DM were modest (best AUC ¼ 0.608 and 0.607) while for lipid traits the prediction R-squared ranged from 16.1 to 29.8%. For psychiatric disorders, the predictive power for SCZ was estimated to be the highest (best AUC 0.820), followed by BD. Predictive performance of other psychiatric disorders ranged from 0.543 to 0.585. Psychiatric traits tend to have more gradual rise in AUC when significance thresholds increase and achieve the best predictive power at higher P-values than cardiometabolic traits.
Introduction
With the rapid advances in genotyping technologies, it is hoped that the advent of our knowledge in disease genomics could be translated to clinical benefits. An important application of genomic data is in disease risk prediction, which can potentially contribute to personalized medicine such as individualized preventive strategies and early diagnosis of diseases (Abraham and Inouye, 2015; . With the advent of genome-wide association studies (GWAS) in the past decade, how far can we realize this goal? In this study, we explored the predictive ability achieved by genetic variants in GWAS studies for a range of complex diseases and traits. We focused on the predictive power of polygenic risk scores (PRSs), as it is perhaps the most widely employed approach for genetic risk prediction. Although in the past only the few genome-wide significant variants were used for prediction, it is increasingly recognized that the variants with lower significance might also contribute to predictive power (Purcell et al., 2009; Wray et al., 2014) . In this study, we assessed predictive ability over the whole range of significance thresholds, up to inclusion of all markers. Polygenic scores combine the effect of multiple genetic variants by summing up allelic counts at different P-value thresholds, usually with weighting by effect sizes. The polygenic score approach is intuitive and is easy to compute and interpret. PRS can also be derived from summary statistics, facilitating its use for risk prediction.
Although numerous GWAS studies have been performed, due to privacy concerns, individual genotype data are often difficult to access. It is even more difficult to gain access to all original genotype data for large consortium studies involving different centers. On the other hand, GWAS summary statistics, often derived from large-scale meta-analyses, are available for a wide range of traits. We made use of summary statistics as they are easily accessible and usually represent the largest studies on the respective traits. We aim to assess the predictive performance of PRS at different significance thresholds. However, cross-validation methods require availability of the entire genotype data and collecting extra validation samples can be costly, especially for multiple diseases. We therefore developed and applied a new framework to evaluate the predictive ability of PRS at arbitrary P-value thresholds, utilizing summary statistics alone. To our knowledge, no previous works have addressed the possibility of estimating predictive power of PRS across any P-value thresholds based on summary statistics only. This approach does not require distributional assumptions on effect sizes or the proportion of associated genetic variants; instead an empirical Bayes approach captures the underlying effect size distribution from the summary statistics data at hand. As the predictive power is studied over a range of P-value thresholds, one can also gain insight into the genetic architecture of the trait.
We explored the predictive power of GWAS variants for ten complex traits, including type 2 diabetes (DM), coronary artery disease (CAD), lipid traits including triglycerides (TGs), high-density lipoprotein (HDL), low-density lipoprotein (LDL) and total cholesterol (TC), schizophrenia (SCZ), bipolar disorder (BD), major depressive disorder (MDD) (using two sets GWAS summary statistics with different case phenotypes) and anxiety disorders. To our knowledge this is also the first survey on the predictive power of GWAS variants based on large-scale meta-analysis results. Implications of the findings will be discussed.
This study extends our previous work on the evaluation of predictive power based on the level of heritability explained (So and Sham, 2010 ). Yet our previous work focused on the predictive power of established genetic variants (i.e. variants passing a stringent significance threshold), while our current work aimed to consider a wider range of variants at any P-value threshold. We developed methods to adjust for the possible inclusion of false positive markers and selection bias. In a related work, Chatterjee et al. (2013) proposed a framework to characterize the connection between sample size and predictive ability of a polygenic model based on the number and distribution of effect sizes of the susceptibility variants. The effect size distribution was estimated by a mixture of exponential distributions accounting for power. A key difference here is that we did not make any distributional assumptions for effect sizes, and the empirical Bayes approach we employed considered the whole range of z-statistics. The approach presented here is much simpler, both mathematically and computationally and does not require the application of Markov Chain Monte Carlo procedures. Dudbridge (2013) derived a theoretical framework to evaluate the power and predictive accuracy of a polygenic score as a function of the sample sizes, the significance threshold for inclusion of markers, the heritability explained and ways of weighting effect sizes. Our emphasis here was different, as we focused on the estimation of predictive performance in actual GWAS datasets based on obtained summary statistics. Also, it is noteworthy to mention in this context that a number of previous researches have studied the potential of genomic risk prediction (Janssens et al., 2006; Mihaescu et al., 2011; Wray et al., 2007) , mostly from simulation approaches.
Methods

Prediction based on PRS
In this study we took advantage of the high-dimensional nature of genomic data and employed an empirical Bayes approach that allows 'learning from the experience of others' (Efron, 2010) . In other words, the underlying true effect size of each variant could be estimated by 'learning' from the summary statistics of other genetic markers, hence taking into account selection bias and the inclusion of false positives in the PRS. The corrected effect sizes could in turn be used to estimate the actual predictive power.
Suppose we wish to predict a trait based on the PRS of each individual. For binary traits, the liability threshold model is assumed. We assumed prediction of a binary trait in this section; however the 'liability' in the following discussions can readily be replaced by a quantitative trait.
The overall liability can be considered to be composed of (i) 'measurable' liability contributed by selected or genotyped variants; (ii) unmeasured liability contributed by the rest of the genetic variants and (iii) liability contributed by environmental factors . Here, we will only focus on component (1) and assume a large number of markers have been genotyped, typically by a GWAS. However, the 'measurable' liability can be composed of a smaller number of variants that are selected by the researcher.
The overall liability can be denoted by
, where x i denotes the standardized allelic count at the ith susceptibility locus and b i is the corresponding true regression coefficient (assuming the entire population is sampled). Here we will consider the case where all x i are independent, as is the case in most PRS studies to date where the variants are LD-pruned or LD-clumped. Further, u represents the total liability contributed by the unknown or untyped genetic variants and e is the total liability contributed by environmental factors.
The true 'measurable' liability, which is the true total liability contributed by selected genetic variants, can be formulated as
In practice, the true regression coefficient is not known and the predicted measurable liability is b
where b b i is the ith regression coefficient obtained from a finite population.
Estimation of the underlying effect sizes
In this section we describe methods to estimate the underlying effect sizes from a set of observed z-statistics. We consider the following formulation for our problem. Denoting the observed z-statistic by z, we have zjd $ Nðd; 1Þ where d ¼ 0 for null variants. Suppose d has a prior density of cðdÞ, the marginal density of z can be expressed by
is the standard normal density function.
If we define wðzÞ ¼ log f ðzÞ uðzÞ , by the properties of exponential families, Efron (2009) showed that
This formula is also known as the Tweedie's formula (Efron, 2010) . Using Tweedie's formula, the corrected estimator of b is
where n is a function to convert the z-statistics to variance in liability explained (Vg). Effect sizes are shrunken towards zero by this formula. f(x) can be estimated by a kernel density as described in using the R function 'density'. As an empirical Bayes approach, there is no need to specify the prior distribution of d.
Deconvolution is avoided as the formula only requires f(z) to be estimated.
We also tested another estimator of effect size by weighting the empirical Bayes estimate (1) by the local true discovery rate:
here fdr i is the local false discovery rate (local fdr) (Efron, 2004 (Efron, , 2011 for marker i. The local fdr measures the probability of H 0 (i.e. no association with outcome) given the observed z-statistic. This approach shrinks small effect sizes more aggressively than (1). For a number of markers whose local fdr are estimated to be one, the effect sizes are shrunken to zero. We also employed another estimator that was recently developed by Mak et al. (2016) :
in which the regression coefficients are weighted by the local true discovery rates.
Computation of local false discovery rate
Local fdr were calculated based on the method described by Efron (2004) and Efron et al. (2001) . We assume a mixture model in which the genetic variants are divided into two groups, null (i.e. no association with the outcome) or non-null. We have
and f 0 ðzÞis the density of z-statistics under the null and f 1 ðzÞis the density under the alternative hypothesis. The overall density of z-statistics can be expressed as a mixture density:
The local false discovery rate is the probability of being null given a z-statistic:
We use the R package locfdr for local fdr calculations. We used cubic splines with 20 degrees of freedom for modelling f(z). Details of the locfdr algorithm can be found in Efron (2004).
Estimating the predictive performance of PRS at different P-value thresholds
Application to binary traits
In this section we show how to estimate the area under the receiver operating curve (AUC) of a PRS model derived from any number of selected variants. Here we assume the PRS is derived from a weighted sum of standardized allelic counts. Consider L meas , the measurable liability contributed by all selected variants and L overall , the overall liability. Note that L overall may be approximated by P ibi x i þ u þ e, whereb is the corrected coefficient estimate obtained from one of the three estimators (1) to (3). The true covariance between L meas and L overall (denoted by r) can then be estimated by P b bb.
The mean vector of [L meas , L overall ] before selection is simply [0, 0] while the covariance matrix is R ¼
We had previously derived an approach for estimating predictive performances of a genetic risk model based on predicted risks at different percentiles of the measurable liability (So and Sham, 2010) . Although our previous work focused on established susceptibility variants, the methodology can be extended to deal with a large panel of GWAS variants. We show below the derivation of AUC for binary traits.
The aim is to derive the distribution of the overall liability after conditioning on the liability of selected variants (the number of variants selected depends on the P-value threshold). After selection on a known value of L meas (the actual measurable liability of selected variants, denoted by l meas ), by Pearson-Aitken formula, the new mean of L overall equals
The new variance of L overall equals
The predicted risk is given by
AUC of PRS for any number of top markers selected can be estimated using the methods described in So and Sham (2010) . Briefly, we evaluated the specificity and sensitivity at different percentile cut-offs (denoted c) of the measurable liability. We then computed the four elements [true positives (TP), true negatives, false positives and false negatives] that are used to define specificity and sensitivity. For instance, for the probability of TPs, we have
# dp where q ¼ rLmeasðpÞ
ð Þ 2 and L meas ðpÞ is the measurable liability at the percentile p. The other elements (true negatives, false positives and false negatives) can be computed readily given Pr(TP). Sensitivity and specificity are calculated using 5000 percentile cut-offs. AUC is then estimated from the ROC graph, integrating over all percentile cutoffs.
Application to quantitative traits
For quantitative traits, the predictive ability can be estimated by the correlation of the predicted outcome (y pred ) and the actual outcome (y): corðy; y pred Þ ¼
Note that y is analogous to L overall and y pred is analogous to L meas , when compared with the previous section on binary traits. Further, y may be approximated by P ibi x i þ u þ e and y pred is computed by P i b b i x i . The square of the above correlation is the prediction R 2 , also known as the coefficient of determination. The above methods can be readily extended to deal with polygenic score constructed from allele counts only. In that case b b in the above formulae is replaced by the sign of b b. An R program to implement the described methodology will be available at the author's website at https://sites.google.com/site/honcheongso/software/predpowergwas.
Simulations and testing on the Northern Finland cohort
Simulations
We performed simulations to assess how well the theoretical estimates of predictive power matches those from a validation set. We assumed a liability threshold model, and simulated training samples of four sizes (5000, 10 000, 15 000 and 20 000). Validation samples with equal sizes were also simulated. We simulated 20 000 independent SNPs and set the proportion of associated markers to be 2.5%. The heritability explained was assumed at 15, 35 and 55%. Liability was simulated as the weighted sum of standardized allelic counts. The coefficients of the polygenic scores were assumed to follow a normal distribution i.e. b $ Nð0; h 2 =MÞ, where M denotes the total number of causal markers. To reduce memory requirements and computational costs, the prevalence was set at 0.45 with people exceeding the liability threshold assuming to be affected. An equal number of cases and controls were then sampled. We computed the Pearson correlations between the actual and estimated AUC and cor(y, y pred ), as well as the associated root mean square errors (RMSEs).The actual predictive performance was derived from the independent validation set while the corrected effect sizes were derived from summary statistics of the training set only. Correlations were computed across a range of P-value thresholds. We set denser thresholds at lower P-values and sparser thresholds at higher P-values, as is done in common practice. The SNPs were ranked by their P-values, and every five SNPs were taken from the top 1000 associations, every 50 for the next 2000, every 500 for the next 2000, and every 1000 for the rest of the SNPs. The simulation was repeated 20 times.
Testing on the Northern Finland Birth Cohort 1966
The proposed methodology for estimating predictive power from summary statistics was also tested on the Northern Finland Birth Cohort (NFBC) 1966 (Sabatti et al., 2009) , accessed from dbGaP (accession number phs000276.v2.p1). Details of the study design were described in Sabatti et al. (2009) . The study subjects were recruited from Northern Finland and all traits were measured at 31 years of age. The Infinium 370cnvDuo array was used for genotyping. Three lipid traits (HDL, LDL and TG) as well as three anthropometric traits (height, weight and waist-hip ratio) were included in the analyses. After standard quality control procedures, 334 458 variants and 5402 individuals were retained for further analyses. LD-clumping was performed in PLINK and on average around 110 000 variants were retained after clumping (please refer to Supplementary Materials for details). A 5-fold cross-validation procedure (repeated four times) was employed to assess our methodology of predictive power estimation. In each run, four-fifths of the subjects were designated as the training set and one-fifth were designated as the testing set. Summary statistics were derived from the training set only. Predictive ability of polygenic scores for different number of top ranked SNPs was computed as in our simulations.
Application to GWAS meta-analyses results:
exploring the predictive ability of polygenic scores for 10 complex traits
We applied our methodology to explore the predictive ability of PRS derived from GWAS for a total of ten complex traits, including DM (Morris et al., 2012) (Otowa et al., 2016) . A description of the datasets is given in Supplementary Table S1 . For MDD, we evaluated the predictive power for two sets of summary statistics, one from the Psychiatric Genomics Consortium (PGC) (Major Depressive Disorder Working Group of the Psychiatric et al., 2013) and the other from the CONVERGE consortium (2015). The latter is a more homogeneous sample of MDD in Chinese women with recurrent depression. Almost all the summary results were derived from meta-analyses of GWAS studies, except for the MDD study by CONVERGE consortium (2015) which is a low-coverage wholegenome sequencing of a large case-control sample. Asb Tweedie:tdr performed the best in our simulations and in the NFBC, estimation of predictive power are based on estimates of b Tweedie:tdr . We performed LD-clumping using samples from the 1000 Genome Project (Auton et al., 2015) as reference panel and the filtered SNPs were included in PRS analyses. LD-clumping was performed in PLINK 1.9 with the commands: -clump-kb 1000 -clumpp1 1 -clump-p2 1 -clump-r2 0.1. Local fdr computation and the correction formulas (1) to (3) were applied to the entire set of test statistics results and the results for the pruned-in SNPs were extracted. We computed predictive power for the 10 traits over a set of 18 P-value thresholds (P ¼ 1e-5, 1e-4, 5e-4, 1e-3, 5e-3, 1e-2, 0.03, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 and 1). Analyses were performed in PLINK 1.9 (Chang et al., 2015) and R 3.2.2.
Results
Simulations and testing on NFBC
Simulations
The results of simulations are shown in Table 1 and Supplementary  Table S2 . In general, the actual predictive performances correlated very well with our analytic estimates. Out of the three methods we included in the analyses,b Tweedie:tdr performed the best, whilẽ b tdr was the worst overall. The correlations were mostly over 0.9 for linear traits but lower for binary traits given the same sample size and heritability explained. For sample sizes of over 5000 cases and 5000 controls, the theoretical estimates of AUC are generally satisfactory. As expected, a larger sample size and higher heritability explained lead to better performance by our method. When the sample sizes reached 20 000, the correlation between the actual and theoretical estimates of predictive power were over 0.99 and 0.95 for linear and binary traits and the RMSE were around 0.01. Supplementary Table S3 shows the Pearson and Spearman correlations and the associated RMSE between cor(y, y pred ) obtained from cross-validation and the results obtained from our theoretical estimation. The results were reasonably good given our limited training sample size of only 4322 subjects. It should be noted that the sample sizes of the other GWAS summary datasets we employed in this study were much larger (Supplementary Table S1 ). As in our simulations, a higher predictive power of PRS was associated with better concordance of theoretical predictive power estimates and the actual predictive performance. The concordance was the lowest for TG, which also had the lowest predictive power from PRS with cor(y, y pred ) ¼ 0.150.b Tweedie:tdr outperformed the other two estimators, consistent with the results from our simulations. Table 2, Supplementary Tables S4 and S5 and Supplementary  Figures S1 and S2 show the predictive power of PRS derived from GWAS, as applied to ten complex traits. For CAD and DM, the best AUC achieved was around 0.61, at P-value thresholds of 1e-3 and 5e-4, respectively. For the four lipid traits, the best prediction R 2 ranged from 16.1% for HDL to 29.8% for LDL, and the best predictive power was achieved at P ¼ 5e-4 for most lipid traits.
Application to the NFBC
Predictive ability of polygenic scores from GWAS: a survey of 10 complex traits
On the other hand, for psychiatric traits, the best AUC values were achieved at higher P-value thresholds, all above 0.03. The predictive power for SCZ was the highest with an AUC of 0.82, followed by BD with the best AUC at 0.68. We also compared our results with prediction metrics obtained in the PGC SCZ study (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014), which estimated the predictive power of GWAS variants by leaving one study out at a time. We note our results are largely compatible with the PGC study, which reported best AUC of $ 0.7-0.8, and achieved the best (or close to best) AUC at P $ 0.01-0.05. The lower predictive power in the PGC might be related to heterogeneity in the cohorts.
The predictive power for MDD and anxiety disorders was lower, in the range of 0.540-0.585. Interestingly, for depression, we observed higher predictive ability of PRS in the MDD CONVERGE (best AUC ¼ 0.585) study than in the PGC Consortium study (best AUC ¼ 0.540).
Regarding the trajectory of predictive performance changes over the range of P-value thresholds, for cardio-metabolic traits the curve tends to peak earlier and then decrease afterwards, while for psychiatric disorders the AUC rise more gradually and tend to plateau at higher P-values (Supplementary Figs S1 and S2).
Discussion
In this study, we developed an approach to evaluate the predictive power achieved by PRS from GWAS summary statistics, and explored the potential for genomic risk prediction of ten complex traits.
Our simulations showed high correlations between the actual and estimated predictive performances, as well as generally low RMSE values. We observed that in simulations that our theoretical estimates are more accurate for larger sample sizes. Most GWAS meta-analyses results to date are usually of large sample sizes. In this study, the smallest sample size was 10 640 and the sizes of many meta-analyses are over 50 000; hence the results should be reasonably reliable.
We explored the predictive potential of PRS for 10 complex traits. For binary outcomes (i.e. prediction of disease risks), polygenic risk prediction for SCZ was the most promising, while prediction for MDD and anxiety disorders were the least satisfactory. SCZ is among the most heritable conditions on our list [h 2 $ 0.81 (Sullivan et al., 2003) ] and the sample size for the SCZ study is also huge, which may explain the relatively high predictive power. BD is N denotes the total sample size. For binary traits, an equal number of cases and controls are simulated (e.g. for n ¼ 20 000, there are 10 000 cases and 10000 controls). Tdr, True discovery rate; h also highly heritable but the sample size collected is much lower than that for SCZ. Interestingly, we found that polygenic scores derived from the MDD CONVERGE study achieved better predictive power than the PGC meta-analyses on MDD. This observation implicates the importance of careful phenotyping of samples, especially for psychiatric disorders. It is believed that MDD does not represent a single and clear-cut diagnostic entity, but a heterogeneous disorder comprising a mixture of patients with different characteristics (Goldberg, 2011) . The same sort of heterogeneity is likely to apply to other psychiatric disorders. By focusing on a subgroup of Chinese women with recurrent depressive disorder and a high rate of melancholic symptoms, the polygenic predictive performance for the CONVERGE cohort was seen to be higher. These findings also suggest a stronger genetic basis of melancholic depression. It should be noted that the meta-analysis on anxiety disorders (Otowa et al., 2016) includes samples with various types of disorders such as generalized anxiety disorders, panic disorders etc. The heterogeneity may have attenuated the predictive power.
The predictive abilities for the two major cardio-metabolic diseases, CAD and DM, were modest with the best AUC at $ 0.61. The prediction R 2 for the lipid traits, were relatively high ranging from 16 to 30%. In clinical practice, genomic predictors might be combined with clinical variables for enhancing the accuracy of predictions. Simultaneously, future studies on the benefits and costeffectiveness of including genetic markers in different circumstances (e.g. different age groups) are warranted to assess the clinical usefulness of polygenic risk prediction. With regards to the trajectory of predictive power changes across P-value thresholds, we observed that relaxing the significance threshold is more beneficial for psychiatric disorders than cardiovascular traits. A possible explanation is that the effects of genetic variants may be more spread-out for psychiatric traits, but more concentrated at the low P-value range for metabolic traits.
We have focused on prediction R 2 and AUC in this study as they are the most commonly employed predictive metrics. There are other prediction metrics available, such as net reclassification improvement, the mean risk difference between affected and unaffected population etc. For example, in selected cases a small improvement in AUC may translate to larger benefits in reclassification in patients (Pencina et al., 2008) . However there are pros and cons of each predictive measure, which are discussed elsewhere (Steyerberg et al., 2010 ). An advantage of our approach is that only summary statistics are required. Hence it can be readily applied to a wide variety of traits to quickly evaluate the predictive potential of genetic variants from large-scale studies. In addition, no assumptions on the distribution of effect sizes or the proportion of null variants are required, rendering the approach flexible enough to deal with diseases of different genetic architecture.
Although we aim to provide a methodology that enables tracking of predictive performances based on summary statistics alone, such an approach cannot replace the validation of predictive models in independent samples, especially if the prediction model is to be applied in a different population. In practice, heterogeneity is often to be expected among cohorts and the risk of cryptic relatedness or inadequately controlled population stratification cannot be ruled out. Therefore, when the prediction model is applied to a new cohort, the observed predictive performance may be inferior to the theoretical estimates (Vilhjalmsson et al., 2015) .
In this study, we have not investigated the predictive power of rare variants. A potential extension of PRS to rare variants is to consider the burden of rare alleles in a gene as a predictor variable, and add up the scores from different genes. If such summary statistics are available, we may also assess the predictive power using the same method.
In this study, we employed LD-clumping procedures, which partially account for LD structure. LD-clumping is a very widely used procedure for constructing PRS. The procedure allows use of univariate weights that are often readily available as summary statistics from large consortiums. However, some variants may have an independent effect which cannot be explained by correlation with a large-effect marker in the LD block, and this cannot be addressed by the current methodology. Recently algorithms such as LDpred (Vilhjalmsson et al., 2015) and others (Hu et al., 2016) have been developed to account for LD structure to improve prediction from PRS. The focus of this study has however been different in that we attempt to develop ways to estimate predictive ability without the need to access raw genotype data. In addition, LDpred requires an extra hyper-parameter (fraction of causal variants) to be tuned in a genotyped sample to obtain the best estimates of regression weights. Hence it cannot be directly applied to forecast predictive power from summary statistics alone. Attenuated correlations among SNPs will likely remain after LDclumping. As remarked by Efron (Efron, 2011) , the Tweedie's approach does not require independence among the z-statistics. The variability of the true effect size estimates may increase compared with the independent case, but the estimates are still largely unbiased. Hence the validity of our method is unlikely to be severely affected by correlated markers.
Besides providing a quick and simple approach to assess the predictive power of a large set of variants, the proposed method could also be useful in planning studies for genetic risk prediction. The researcher can evaluate at what range of significance thresholds the predictive power is likely to be the best, and decide on the optimal number of markers to include for genotyping. One may also make use of this methodology in selecting appropriate P-value threshold for association tests with PRS, alleviating the multiple testing burden. The trajectory of predictive performances itself might also shed light on the genetic architecture of respective diseases.
In summary we presented a novel framework to evaluate the predictive power of PRS using GWAS summary statistics, and explored the predictive abilities for a range of complex traits. It is hoped that risk prediction based on genomic profiles might lead to more personalized preventive and screening strategies for early detection of diseases. Given that GWAS have flourished in the past decade with large sample sizes already accumulated for a number of complex diseases, we hope the current survey will provide a useful assessment of the predictive power achievable by polygenic scores for these diseases.
